PharmachubTM
UK-registered clinicians · GLP-1 treatments

Treatments
that work.

Mounjaro and Wegovy are clinically proven GLP-1 receptor agonists, prescribed only where appropriate after a thorough clinical assessment by a UK-registered prescriber.

UK prescribers
Safety first
1:1 consultation
Ongoing support
Treatment pens on a clean background
Mounjaro
Tirzepatide

Mounjaro

A dual GIP & GLP-1 receptor agonist. From £219 per month.

Learn more
Wegovy
Semaglutide

Wegovy

GLP-1 receptor agonist. From £199 per month.

Learn more
Tirzepatide · GIP & GLP-1

Mounjaro

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It works by mimicking two gut hormones to reduce appetite and improve insulin sensitivity. Clinical trials showed an average of 22% body weight reduction over 72 weeks.

  • Dual GIP & GLP-1 mechanism
  • Weekly self-injection pen
  • MHRA-licensed supply only
  • Dose titrated by your clinician

Select dose

Mounjaro 2.5mg
£219
per monthly supply
Includes clinical consultation & aftercare
Mounjaro pen
Wegovy pen
Semaglutide · GLP-1

Wegovy

Wegovy (semaglutide) is a GLP-1 receptor agonist that regulates appetite by mimicking the hormone GLP-1. Clinical trials demonstrated an average 15% reduction in body weight. It is MHRA-approved specifically for weight management.

  • MHRA-approved for weight management
  • Weekly self-injection pen
  • Gradual dose escalation protocol
  • Clinically reviewed at each stage

Select dose

Wegovy 0.25mg
£199
per monthly supply
Includes clinical consultation & aftercare

Mounjaro vs
Wegovy

Both are effective GLP-1 treatments. Your clinician will recommend the most appropriate option based on your health profile.

Mounjaro and Wegovy pens side by side
Feature
Mounjaro
Wegovy
Active ingredient
Tirzepatide
Semaglutide
Mechanism
Dual GIP & GLP-1
GLP-1 only
Average weight loss
~22% over 72 weeks
~15% over 68 weeks
Injection frequency
Once weekly
Once weekly
Starting dose
2.5mg
0.25mg
Maximum dose
15mg
2.4mg
MHRA licensed
Yes
Yes
Starting price
From £219/mo
From £199/mo

* Average weight loss figures are from published clinical trial data (SURMOUNT-1 and STEP 1). Individual results vary. Treatment is only provided where clinically appropriate.

Clinical eligibility check

Are you eligible
for treatment?

GLP-1 treatments are not suitable for everyone. Your clinician will carry out a full assessment before making any recommendation.

General eligibility criteria

  • BMI of 30 or above (or 27+ with a weight-related condition)
  • No history of personal or family medullary thyroid cancer
  • Not pregnant, breastfeeding, or planning pregnancy
  • No current pancreatitis or severe GI conditions
  • Willing to engage with lifestyle support as part of the programme

These are general indicators only. Your suitability will be assessed individually by your clinician. Treatment will not be prescribed where it is not clinically appropriate.

Start your clinical
consultation today.

A Pharmachub clinician will review your health history and, where appropriate, recommend a treatment plan tailored to you.

Common questions